Epstein–Barr virus
Virus of the herpes family
Follow Epstein–Barr virus on Notably News to receive short updates to your email — rarely!
We include updates on Multiple sclerosis, Lupus, Multiple myeloma, Infectious mononucleosis, Alice in Wonderland syndrome, Stomach cancer, Burkitt lymphoma, Diffuse large B-cell lymphoma, Leiomyosarcoma, Hairy leukoplakia, Nasopharyngeal carcinoma, T-cell lymphoma, MOG antibody disease, Mosquito bite allergy, Plasmacytoma, Primary central nervous system lymphoma ... and more.
| January 14 2025 |
Leiomyosarcoma
Deborah Finck, Tiktoker and Nanny 911 star, died from leiomyosarcoma at the age of 57.
|
| 2024 | Scientists published research tracing MS-risk gene variants to ancient migration from the Yamnaya culture, discovering that these genetic variants originally protected cattle herders from animal diseases, but now contribute to increased MS risk due to modern lifestyles and improved hygiene. |
| 2024 |
Multiple myeloma
FDA expanded CAR T-Cell therapy approval to include multiple myeloma patients who have relapsed after only a single line of treatment, broadening treatment options for patients earlier in their disease progression.
|
| September 2024 | Ocrelizumab/hyaluronidase was approved for medical use in the United States. |
| September 2023 |
Multiple myeloma
Motixafortide (Aphexda) was approved for medical use in the United States, expanding treatment options for multiple myeloma.
|
| August 2023 |
Multiple myeloma
Talquetamab (Talvey) and elranatamab (Elrexfio) were approved for medical use in the United States, providing new treatment options for multiple myeloma patients.
|
| March 2023 |
Diffuse large B-cell lymphoma
Glofitamab (Columvi) was approved for medical use in Canada as a bispecific monoclonal antibody treatment for DLBCL.
|
| 2022 | Nearly one million people in the United States were diagnosed with Multiple Sclerosis (MS). |
| 2022 | A scientific review found that nabiximols (a cannabis-based medication containing THC and CBD) can potentially reduce short-term spasticity severity in multiple sclerosis patients, though with potential neurological side effects. |
| 2022 | A groundbreaking study of 10 million soldiers' historical blood samples revealed a critical link between Epstein-Barr virus infection and multiple sclerosis, showing that the risk of multiple sclerosis increases over 30-fold after EBV infection. |
| 2022 | A large-scale study of 10 million people over 20 years suggested EBV as the leading cause of multiple sclerosis, revealing that a recent EBV infection increases the risk of developing multiple sclerosis by 32-fold. |
| December 16 2022 |
Epstein–Barr virus–associated lymphoproliferative diseases
Tabelecleucel (Ebvallo) was granted marketing authorization under 'exceptional circumstances' as a monotherapy for treating EBV+ LPD in patients aged 2 years and older who have received a hematopoietic stem cell transplantation and experienced refractory or relapsed EBV+ LPD after at least one prior therapy.
|
| September 2022 |
Lupus
Researchers at the University of Erlangen-Nuremberg published groundbreaking results of a lupus treatment using genetically altered CAR T cells. Five patients (four women and one man) received transfusions that eliminated aberrant B cells, successfully driving the disease into remission and allowing patients to discontinue lupus medication.
|
| February 2022 |
Multiple myeloma
Ciltacabtagene autoleucel (Carvykti) was approved for medical use in the United States, indicated for treating adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
|
| 2021 | Ponesimod was approved for management of CIS, relapsing MS, and SPMS in the U.S., and relapsing-remitting MS in Europe. |
| 2021 |
Multiple myeloma
FDA approved idecabtagene vicleucel, the first cell-based gene therapy for treating adults with relapsed or refractory multiple myeloma who have received at least four prior therapies.
|
| April 2021 |
Diffuse large B-cell lymphoma
FDA approved loncastuximab tesirine as a treatment for adult patients with relapsed or refractory DLBCL after systemic therapy.
|
| 2020 | Global prevalence of multiple sclerosis reached approximately 2.8 million people, highlighting the significant worldwide impact of this neurological disorder. |
| 2020 | Ozanimod was approved for management of CIS, relapsing MS, and SPMS in the U.S., and relapsing-remitting MS in Europe. |
| 2020 |
Leiomyosarcoma
Deborah Finck was diagnosed with leiomyosarcoma.
|
| 2020 |
MOG antibody disease
Multiple studies conducted to investigate the distinctive characteristics of MOG antibody disease (MOGAD) lesions, revealing significant differences from multiple sclerosis (MS) in terms of CNS topographical distribution, demyelination type, and inflammatory response.
|
| August 2020 |
Diffuse large B-cell lymphoma
FDA approved tafasitamab in combination with lenalidomide as a treatment for adult patients with relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL).
|
| July 2020 | Researchers reported the first complete atomic model of the Epstein-Barr virus nucleocapsid, which included the icosahedral capsid, capsid-associated tegument complex (CATC), and dodecameric portal – providing a comprehensive structural understanding of the virus's genome translocation apparatus. |
| February 2019 |
Extranodal NK/T-cell lymphoma, nasal type
A phase 2 clinical study sponsored by ViGenCell Inc. begins recruitment for testing cytotoxic T-lymphocyte (CTL) treatment on patients in complete remission from Extranodal NK/T-cell lymphoma, nasal type (ENKTCL-NT) to determine if the treatment can prolong remissions.
|
| September 2018 |
Extranodal NK/T-cell lymphoma, nasal type
A study examining the effects of brentuximab vedotin on EBV-positive, CD30-positive lymphomas is estimated to be completed.
|
| March 2017 | The FDA approved ocrelizumab as the first drug treatment for primary progressive multiple sclerosis in adults, with requirements for several Phase IV clinical trials. |
| 2011 | Mitoxantrone became the first medication approved for treating secondary progressive multiple sclerosis, with tentative evidence showing it could moderately slow disease progression and decrease relapse rates over two years. |
| 2011 |
Alice in Wonderland syndrome
By month 8 after the initial treatment, the patient's symptoms returned, prompting a second rTMS treatment which again resulted in complete remission.
|
| 2011 |
Alice in Wonderland syndrome
A patient with verbal auditory hallucinations was treated using repetitive transcranial magnetic stimulation (rTMS) on Brodmann's area 40. After two weeks of treatment, the patient experienced full remission of hallucinations and sensory distortions.
|
| August 2011 |
Alice in Wonderland syndrome
By the eighth month after initial treatment, the patient's symptoms of Alice in Wonderland Syndrome returned, prompting a second treatment which again resulted in complete remission.
|
| March 2011 |
Lupus
FDA approved belimumab, a fully human monoclonal anti-BAFF antibody, as a treatment for lupus after the BLISS-76 study tested its effectiveness in targeting B lymphocytes.
|
| 2010 |
Leiomyosarcoma
Irwin Barker died from leiomyosarcoma.
|
This contents of the box above is based on material from the Wikipedia articles Lupus, Epstein–Barr virus, Alice in Wonderland syndrome, Diffuse large B-cell lymphoma, Multiple sclerosis, MOG antibody disease, Multiple myeloma, Extranodal NK/T-cell lymphoma, nasal type, Leiomyosarcoma & Epstein–Barr virus–associated lymphoproliferative diseases, which are released under the Creative Commons Attribution-ShareAlike 4.0 International License.